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Abstract
Background: The aim of this study was to develop and validate a Portuguese version of The Subjective
Experiences of Psychosis Scale (SEPS) for use in Portuguese-speaking populations in order to provide a self-report
instrument to assess and monitor dimensions of psychotic experiences, translating patient’s perspective and
experience in terms of recovery from psychosis.
Methods: The sample consisted of 30 participants with psychotic disorders who had recently experienced
delusions or hallucinations. The SEPS was completed along with other observer-based assessments and self-report
questionnaires, such as the Brief Psychiatric Rating Scale, the Insight and Treatment Attitudes Questionnaire and the
Function Assessment Short Test.
Results: Two main factors representing the positive and negative components of each subscale were identified.
We obtained good internal consistency and test-retest reliability for the positive and negative components of all
subscales. The subscales of SEPS correlated with observer-based assessments and self-report questionnaires.
Conclusions: The Portuguese version of the SEPS is a useful tool in the assessment and monitoring of psychotic
symptoms.
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Background
Many instruments have been developed to assess psychotic
symptoms and treatment effects. Such instruments have
proven to be of interest in clinical practice and research
because they allow for better symptom monitoring, treat-
ment adaptation, and general improvement in the quality
of mental health services. Most of these measures are
observer assessments conducted by mental health profes-
sionals through interviewing and patient observation [1].
On the other hand, self-report questionnaires are based on
patients’ perception of their mental health and treatment,
without interference from mental health professionals and
are, therefore, regarded as measures of subjective evalu-
ation [2]. Self-report instruments - taking into account
limitations to their use in psychotic patients such as lack
of insight, cognitive deficits, and even metacognitive skills
- have several advantages over observer assessments,
namely their ease of use [3, 4]. They can also provide real-
life information on perceived effects of treatment, which
can only be described by the patient [2]. However, most of
these instruments focus only on presence and severity of
symptoms and do not take into account other dimensions
that are relevant for patients, such as the positive and
negative effects of the treatment [1]. Factors influencing
subjective response to antipsychotic drugs include insight,
previous experience of medication, health beliefs and the
quality of the therapeutic relationship, and it is now widely
accepted that patients’ subjective experience of medication
should be given more consideration in treatment outcome
measures [5].
The patient’s perspective is of particular importance in
cases of severe mental illness where multiple areas may be
affected. While some patients may value the reduction of
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symptoms or side effects, others may view social relations
or global functioning as more important. Thus, two indi-
viduals with identical scores in a set of instruments
focused only on psychopathological symptoms may have
very different feelings towards their mental illness [6].
More importantly, a traditional perspective that psychotic
disorders are associated with lack of insight – attributable
to cognitive deficits or adaptation to disease, avoiding
painful realities – should acknowledge that awareness of
illness is intertwined with a person’s narrative understand-
ing of his own life [7, 8].
The definition of recovery in psychosis has been ad-
dressed differently, depending on whether it is seen from a
personal or clinical perspective. The clinical perspective is
measured in terms of alleviation of symptoms associated
with an improvement [9]. This view has been widely
adopted [10] since it has been shown that psychotic symp-
toms contribute to a marked disruption in social and occu-
pational functioning [11]. Consequently, a large number of
instruments for measuring symptoms and functioning have
been developed with high levels of reliability, reinforcing
the idea of recovery as the reduction of psychiatric symp-
toms [12]. Such instruments have proven to be of interest
in clinical practice and research because they allow a better
symptom monitoring, treatment adaptation and general
improvement in the quality of mental health services. How-
ever, most of these instruments focus on presence and
severity of symptoms only, and do not take into account
the multidimensional process of recovery as reported by
patients [1, 13].
Although the classical hallmark of schizophrenia is the
deteriorating course and its negative impact in patient’
lives, it is currently accepted that recovery is possible
even for those individuals [14]. In fact, studies have
shown diverse prognostic patterns in the first episode of
psychotic patients [15]. The personal perspective of
recovery occurs as an evolving and adjusting process
through which the subject overcomes main challenges
such as threats to its sense of identity, loss of previous
ways of understanding the world, acknowledging losses
in one’s life and accepting oneself as an ordinary yet pro-
active individual, achieving self-determination and a mean-
ingful life [9, 16]. This does not necessarily mean a decline
in psychiatric symptoms but rather the achievement of spe-
cific recovery goals defined by the patient [17]. In mental
health policy this definition highlighted the importance of
taking into account the patient’s subjective experiences,
needs and preferences in evaluation and treatment [18].
However, its inherent subjectivity has made it more difficult
to measure recovery adequately and to build these instru-
ments [19].
Wood and cols [13] attempted to ascertain which factors
elicited by patients contributed to recovery and how those
related to a reduction in symptoms. Four main themes
emerged: impact on mental health, individual change and
adaptation, social redefinition, and development of coping
strategies. Moreover, a similar and more recent study [20]
identified further perspectives: collaborative support and
understanding; emotional change through medical and
social support; increased functionality and attainment of
occupational goals; and recovery focused on individual fac-
tors. In both studies the importance of reduction of psych-
otic symptoms was taken into account for some patients
whilst for others this concern was displaced for the absence
of their negative impact, rather than their presence. Im-
portantly, recovery seems to be interpreted as a multidi-
mensional process and, therefore, the conceptualization of
recovery must consider both symptoms and personal
factors [10]. Studies have emphasized the importance of
developing instruments that explore both clinical and per-
sonal aspects of recovery [12]. However, most of these
studies have focused on each component individually, war-
ranting the development of tools that measure recovery in
a holistic fashion.
The Subjective Experiences of Psychosis Scale (SEPS)
[1] has emerged from the need to provide a self-report
scale of psychotic experiences, which would reflect the
various dimensions of psychosis and allow the evaluation
of treatment effects over time. In order to translate the
experience and perspective of patients on recovery, the
conception of the SEPS followed two distinct phases. In
the first phase, items of the scale were generated by
identifying in the literature relevant factors for the
conceptualization of recovery from the patient’s perspec-
tive. In the second phase, patients with a history of
psychosis were asked to put forward suggestions on the
content and format of the scale. Forty-one items were
derived and then organized into three categories: (1) im-
pact of psychotic experiences in the mental health and
well-being (29 items); (2) impact of support (treatment,
social support, substance abuse, and religious beliefs) in
psychotic experiences (6 items); and (3) severity of the
different dimensions of psychotic experiences (6 items).
Participants are instructed to rate the impact of their
experiences of psychosis during the previous week.
Each item in the subscales 1 and 2 is listed twice for
the positive and negative impact. For example, in the
first item of the first subscale the following question is
asked: “In the past week, how have your experiences
affected your ability to socialize?”. Participants are
instructed to rate both the positive and negative aspects
of their ability to socialize, while using a five-point
Likert scale, varying from (1) “Not at all” to (5) “Very
Much”. For subscale 2, items can be quoted as “not
applicable” if the aspect in question has not verified.
The SEPS showed good internal consistency and test-
retest reliability and demonstrated good validity against
other measures of psychosis, appearing as a valid and
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reliable self-report scale to assess and monitor dimen-
sions of psychotic experiences [1].
The aim of our study was to translate, adapt and validate
a Portuguese version of SEPS [1] in order to provide a
multidimensional scale to assess and monitor dimensions
of psychotic symptoms. We intended to determine the
internal consistency, reliability, validity and applicability of
this instrument in the Portuguese population. The study
hypotheses were that the scale presented good internal
consistency (α of at least 0.6), reliability in test-retest, and
good validity in relation to other measures of psychosis
(criterion validity). More specifically, we expected that the
negative components of the subscales of SEPS were posi-
tively correlated with measures of symptoms (general
symptoms, functioning, depression, anxiety), and negatively
correlated with recovery and that the positive components
of SEPS were positively correlated with recovery and nega-
tively correlated with measures of symptoms. Following
previous studies of predictors of recovery using more trad-
itional definitions, focused on symptom remission or non-
recurrence, we also addressed relevant psychosocial and




This project was approved by the Ethics Committee of the
Faculty of Medicine, University of Coimbra (REF 12-CE-
14). Patients were recruited from the outpatient clinic of
the Psychiatry Department of the Coimbra Hospital and
University Centre. After describing the aims and proce-
dures of the study and ensuring confidentiality, partici-
pants were invited to voluntarily participate in the study.
All individuals signed written informed consent before
any procedure.
Patients were included in the study if they met the
following inclusion criteria: (1) diagnosis of schizophrenia
or other psychotic disorder (schizophreniform disorder,
schizoaffective disorder, delusional disorder, brief psych-
otic disorder and substance-induced psychotic disorder),
or bipolar disorder type I (with at least one episode with
psychotic features) based on the DSM-IV-TR criteria [11];
(2) recent experience (previous month) of delusions or
hallucinations verified by the Brief Psychiatric Rating Scale
(BPRS; [22]); (3) clinical capability to conscientiously
understand the purpose and procedures of this research
project and directly written informed consent; (4) aged
between 18 and 65.
Exclusion criteria included: (1) inability to complete
assessment questionnaires; (2) poor command of the
Portuguese language; (3) severe cognitive deterioration;
(4) neurological disorders; (5) comorbid drug or alcohol
abuse or dependence. The study was approved by the
local ethics committee and informed consent was obtained
from all participants.
The sample consisted of 30 participants (10 females
and 20 males) aged between 18 and 63 years (M = 38.27,
SD = 11.87). Demographic information can be found in
Table 1. All patients were medicated with psychotropic
drugs: 12 with atypical and 7 with typical antipsychotics,
3 with both typical and atypical antipsychotics, and 8
with mood stabilizers and antipsychotics.
Instruments
A structured questionnaire was used to collect demo-
graphic information. Three observer assessments were
used: the Brief Psychiatric Rating Scale to rate overall




























Schizoaffective disorder 2 (6,7)
Brief psychotic disorder 2 (6,7)
Bipolar disorder type I 11 (36,7)
Duration of disorder, mean years (SD)
7,70 (7,72)
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psychiatric symptoms (BPRS; [23]), the Insight and Treat-
ment Attitudes Questionnaire to assess insight and atti-
tudes towards treatment (ITAQ; [24]) and the Portuguese
version of the Function Assessment Short Test to measure
general functioning [25] (FAST; [26]).
The SEPS and four other self-report questionnaires were
used: the Recovery Assessment Scale (RAS; [27]) was used
to ascertain how the SEPS related to reported levels of
recovery; the Portuguese version of the Brief Symptom
Inventory [28] (BSI, [29]) was used to assess overall psy-
chiatric symptoms; the Portuguese version of the Beck
Depression Inventory (BDI-II; [30]) [31], was used to
assess depressive symptoms. Medication adherence was
verified by the Portuguese version of the Medication
Adherence Rating Scale [32] (MARS; [33]). All scales have
shown to have good reliability and validity in samples of
patients with psychosis.
Procedure
To ensure content validity the original version was trans-
lated and adapted into Portuguese language by three
Portuguese mental health professionals with proficiency in
English. All versions were compared and modified until a
consensus version was agreed upon. Back-translation to
English was then performed by a bilingual mental health
professional with no prior knowledge of the scale. The
back-translation was sent to the authors of the original
scale for revision and official approval of the Portuguese
version.
Participants were recruited from the outpatient clinic
of the Psychiatry Department at the Coimbra Hospital
and University Centre, a tertiary care centre. The study
was conducted over two separate phases. In phase one,
the demographic questionnaire and all scales were com-
pleted. The ITAQ and the FAST interviews were carried
out by the first author and the BPRS was conducted by
the referring psychiatrist and then reviewed by one of the
authors. All remaining scales were completed independ-
ently by participants, with no interference from mental
health professionals.
In order to investigate test-retest reliability of the Portu-
guese version of the SEPS, a second phase was conducted
3–4 weeks later, in which participants were asked to
complete the SEPS again. Eighteen participants completed
this phase, given that 12 patients were unavailable to return
for re-evaluation.
Statistical analysis
Statistical analysis was performed using the software
SPSS Statistics 21 (IBM Corporation, Armonk, NY,
USA). Faced with the normal distribution of the sample
data, one-way ANOVAS, t-tests and Pearson’s r were
performed to explore some differences and relationships
between the variables in use. This study aims to validate
a scale and, therefore, an exploratory factor analysis (PCA
method) was performed to assess the construct validity.
Pearson’s correlations between the SEPS and other compet-
ing/comparison measures were accomplished to assess
criterion validity the Cronbach’s alpha was used to calculate
internal consistency. Pearson correlation and Intraclass
Correlation Coefficient (ICC) were used to assess reliability
test-retest.
Results
Thirty participants (10 females and 20 males) were enrolled
in the study and their demographic characteristics are sum-
marized in Table 1. All 30 participants completed phase
one of the study but only 18 completed the second phase.
Due to the limited number of participants in the sample,
the “not applicable” option in subscale 2 (“Impact of Sup-
port in Experiences”) had a negative impact on the results,
since these data were not taken into account in the statis-
tical analyses. The items listed comprised: “Support from
other service users”, “Alcohol and/or drug use” and “Spir-
ituality/Religious Beliefs”. To address this lack of data, the
tendency to response to items model could be taking into
account. However, due to the specificity of each item, the
cold deck imputation method was preferred, and the miss-
ing values were replaced by the mean of the other partici-
pant’s responses in the three questions [34].
Descriptive analysis
Descriptive analyses were conducted to explore the socio-
demographic and clinical characteristics of the sample.
Table 2 presents descriptive statistics for the measures of
symptomatology, insight and treatment adherence for each
of the diagnoses in the sample. In general, patients with a
diagnosis of schizophrenia presented higher scores in gen-
eral symptoms (BPRS), and lower levels of insight (ITAQ)
Table 2 Descriptive statistics of instruments for each diagnosis
Diagnosis BPRS mean (SD) ITAQ mean (SD) FAST mean (SD) RAS mean (SD) MARS mean (SD)
Schizophrenia 39.20 (8.39) 14.92 (6.90) 15.38 (10.71) 152.00 (22.63) 6.85 (2.27)
Schizoaffective 35.50 (4.95) 19.50 (3.54) 19.50 (6.36) 152.93 (18.68) 6.50 (0.71)
Brief Psychotic 32.50 (2.12) 18.00 (1.41) 13.00 (9.90) 166.00 (8.49) 6.50 (0.71)
Bipolar I 37.36 (7.97) 19.60 (4.06) 19.20 (17.93) 157.18 (11.33) 7.10 (2.03)
SD standard deviation
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and recovery (RAS). Patients with bipolar disorder showed
higher levels of insight and treatment adherence (MARS).
Functionality levels (FAST) were lower for schizoaffec-
tive and bipolar patients. A one-way ANOVA, per-
formed to compare the means between the different
diagnoses, showed that none of the differences were
significant.
A Student’s t-test for independent samples was used to
determine whether there were significant differences be-
tween gender and the scores obtained in each subscale of
the SEPS. Gender differences in the various subscales were
small, and men ranked higher in SEPS’s negative aspects.
The only significant difference found was for the subscale
“Positive Impact of Support in Psychotic Experiences”, t
(28) = 3.45, p = 0.002, showing that women identified a
greater positive impact of support on their experiences
(M = 21.40, SD = 2.17) than men (M= 10.17, SD = 3.61).
A one-way ANOVA was performed to check whether
there were significant differences among the diagnoses
and the scores on each of the subscales of SEPS (Table 3).
No statistically significant differences were observed. The
descriptive statistics for each of the subscales of SEPS in
both assessment stages, as well as for gender and diagnoses
separately, are presented in Table 3. Only the responses
provided by the participants in the first phase of the assess-
ment were used for the analysis of gender and diagnosis.
In the analysis of correlations between the positive and
negative components of each subscale, there was a signifi-
cant positive correlation between the positive component
of subscale “Impact of Experiences” and the positive
component of the subscale “Dimensions of Experiences”.
The effect size of this correlation was large (r = 0.72, p =
0.000). The negative component of the subscale “Impact of
Experiences” showed a significant positive correlation with
the negative component of the subscale “Impact of Support
in Experiences”, and with the negative component of sub-
scale “Dimensions of Experiences”, also both with a large
effect size (r = 0.57, p =0.001 and r = 0.50, p =0.005 respect-
ively) (see Table 4).
Factor analysis
For the purpose of determining whether the Portuguese
version of SEPS shows the same factor solution (two factors
for each subscale - positive and negative) than that of the
original validation study (1), we decided to run an explora-
tory factor analysis with the PCA method. In order to verify
this separation of factors, a principal component analysis
was applied to each subscale of the SEPS, using a varimax
rotation. Due to the clinical nature of the sample, the
number of participants was limited, thus involving con-
straints in the factor analysis. However, in order to verify
the suitability of the data for conducting a factor analysis,
the correlation matrix was examined to ensure that there
was no multicollinearity or singularity. The Kaiser-Meyer-
Olkin (KMO) coefficients were also explored to verify the
adequacy of the sample [35]. The coefficient for the first
subscale (“Impact of Experiences”) was weak, yet accept-
able (KMO= 0.50). Both the second (“Impact of Support
in Experiences”) and third subscales (“Dimensions of
Experiences”) yielded moderate coefficients (KMO= 0.60
Table 3 Descriptive statistics for the subscales of SEPS and for gender and diagnosis
Phase 1 Phase 2
Subscale Total (n = 30) Male (n = 20) Female (n = 10) Total (n = 18)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Positive impact 71.47 (24.32) 73.85 (26.15) 66.70 (20.58) 66.56 (21.62)
Negative impact 62.97 (21.26) 64.00 (21.03) 62.45 (21.91) 60.17 (20.43)
Positive support 18.53 (3.78) 17.10 (3.61)** 21.40 (2.17)** 16.28 (3.88)
Negative support 9.37 (3.07) 9.80 (3.38) 8.50 (2.22) 7.67 (2.97)
Positive dimensions 4.73 (2.32) 4.95 (2.37) 4.30 (2.26) 4.33 (1.64)
Negative dimensions 9.40 (3.59) 9.75 (3.71) 8.70 (3.40) 9.78 (3.25)
Subscale Schizophrenia Brief Psychotic Bipolar I Schizoaffective
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Positive impact 73.07 (24.90) 67.00 (15.56) 71.45 (24.32) 64.00 (14.14)
Negative impact 60.20 (22.27) 73.50 (10.61) 65.18 (23.37) 61.00 (14.14)
Positive support 16.93 (4.16) 23.00 (1.41) 19.27 (2.28) 22.00 (2.83)
Negative support 9.40 (3.20) 10.50 (2.12) 8.91 (2.77) 10.50 (6.36)
Positive dimensions 4.93 (2.37) 4.00 (2.83) 4.82 (2.44) 3.50 (2.12)
Negative dimensions 8.67 (3.39) 8.00 (4.24) 11.00 (3.66) 7.50 (3.54)
SD standard deviation
**p <0.01
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and KMO= 0.63 respectively). The values for the Bartlett
test (29) were significant for the three subscales (p <0.05).
As it happened in the original study, for each of the three
analyses two main factors emerged (for eigenvalues higher
than 1 and loadings above 0.4 taken as significant). For
the first subscale, two factors contributed to 36.50 % of
explained variance (40.13 %, in the original study), with
factor 1 (Positive Impact of Experiences) contributing to
18.34 % of the variance (21.54 %, in the original study)
and factor 2 (Negative Impact of Experiences) contribut-
ing to 18.16 % of the variance (18.59 %, in the original
study). For the second subscale two factors that explain
40.69 % of the variance (54.29 %, in the original study)
were identified. Factor 1 (Positive Impact of Support in
Experiences) contributed to 21.59 % of the variance
(29.49 %, in the original study) and factor 2 (Negative
Impact of Support in Experiences) to 19.11 % of the vari-
ance (24.80 %, in the original study). For the third sub-
scale, two factors contributed to a total explained variance
of 75.40 % (60.12 %, in the original study). Factor 1 (Posi-
tive Dimensions of Experiences) contributed to 45.67 % of
the variance (33.47 %, in the original study) while the
second factor (Negative Dimensions of Experiences) con-
tributed to 29.73 % of the variance (26.65 %, in the original
study).
Reliability and internal consistency
To explore the reliability of SEPS, the Cronbach’s alpha
was used for the calculation of internal consistency of
each subscale and the Pearson correlation coefficient (r)
and ICC to ascertain the test-retest reliability between
the two administrations.
Regarding internal consistency, excellent values were
obtained for the positive and negative components of
the subscale “Impact of Experiences” (both with α =
0.96). The values for the positive and negative compo-
nents of the subscale “Impact of Support in Experiences”
were acceptable (α = 0.61 and α = 0.67 respectively), and
for positive and negative components of the subscale
“Dimensions of Experiences” the values ranged from
excellent to good (α = 0.92 and α = 0.84 respectively).
After the analysis of the correlation matrix for each sub-
scale, which relates each item to the total correlation of
the test, it was found that there was no item that if elimi-
nated would significantly increase the internal consistency
of a subscale (see Table 5).
For the test-retest reliability assessment, the values of
Pearson coefficients were statistically significant for the
positive and negative components of each subscale and
the size effect was large for all of them (r = 0.93, p <0.01
and r = 0.84, p <0.01 for the components of the subscale
“Impact of Experiences”, r = 0.52, p <0.05 and r = 0.72, p
<0.01 for the components of the subscale “Impact of
Support in Experiences”, r = 0.66, p <0.01 and r = 0.77, p
<0.01 for the components of the subscale “Dimensions
of Experiences”) (see Table 5). In addition, and in order
to deepen the analysis of test-retest reliability, we decided
to calculate the Intraclass Correlation Coefficient (ICC)
using the absolute agreement method (see Table 5).
Correlation analyses
The criterion validity of SEPS was verified using bivariate
correlation analysis and through the Pearson correlation
coefficient (r). We obtained internal consistency values
considered appropriate for BPRS, FAST, BSI, RAS and
BDI-II (α = 0.78, α = 0.94, α = 0.98, α = 0.85 and α = 0.86
respectively).
The Global Severity Index (GSI) of BSI showed sig-
nificant positive correlations of large effect size with
the negative components of the subscales of “Impact of
Experiences” and “Impact of Support in Experiences”, and
Table 4 Correlations between subscales of SEPS
Subscale Positive impact Negative impact Positive support Negative support Positive dimensions Negative dimensions
Positive impact – – – – – –
Negative impact 0.13 – – – – –
Positive support 0.25 0.30 – – – –
Negative support 0.34 0.57** 0.10 – – –
Positive dimensions 0.72** −0.12 0.21 0.09 – –
Negative dimensions 0.19 0.50** 0.05 0.31 0.21 –
**p <0.01






Positive impact 0.96 0.93**/ 0.962
Negative impact 0.96 0.84**/ 0.903










**p <0.01; *p <0.05
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of average effect size with the negative component of the
subscale “Dimensions of Experiences” (r = 0.74, p <0.01, r =
0.52, p <0.01 and r = 0.41, p <0.05 respectively). The BDI-II
correlated negatively with the positive components of the
subscales and positively with the negative components of
the subscales. A significant positive correlation of large ef-
fect size was founded between the BDI-II and the negative
component of the subscale “Impact of Experiences” (r=
0.53, p <0.01).
The RAS correlated positively with the positive com-
ponents of the subscales and negatively with the negative
components of the subscales. These correlations were
significant and with an average effect size for the positive
components of subscales “Impact of Experiences” (r =
0.40, p <.05), “Impact of Support in Experiences” (r =
0.39, p <0.05) and “Dimensions of Experiences” (r = 0.40,
p <0.05), and for the negative component of subscale
“Impact of Experiences” (r = -0.43, p <0.05).
The dimensions Anxiety and Psychoticism of the BSI
were significantly correlated with all the negative compo-
nents of the subscales of SEPS and the effect size ranged
from large to average (r = 0.75, p <0.01 and r = 0.55, p <0.01
respectively, for the subscale “Impact of Experiences”, r =
0.45, p <0.05 and 0.55, p <0.01 respectively, for subscale
“Impact of Support in Experiences”, r = 0.41, p <0.05 and
r = 0.39, p <0.05 respectively, for the subscale “Dimensions
of Experiences”) (see Tables 6 and 7).
The BPRS showed a significant positive correlation of
large effect size with the negative component of the sub-
scale “Dimensions of Experiences” (r = 0.51, p <.01). The
FAST correlated negatively with the positive components
of the subscales and positively with the negative compo-
nents subscales. There was a significant correlation, of
average effect size, between FAST and the negative com-
ponent of the subscale “Impact of Experiences” (r = 0.44,
p <0.05). The Depression item of the BPRS was signifi-
cant correlated with the negative components of the
subscales “Impact of Experiences” (r = 0.47, p <0.01) and
“Dimensions of Experiences” (r = 0.45, p <0.05), and
these correlations showed an average effect size. The
Anxiety item of the BPRS showed significant positive
correlations, with an effect size ranged from average to
large, with the negative components of the subscales
“Impact of Experiences” (r = 0.41, p <0.05) and “Dimen-
sions of Experiments” (r = 0.50, p <0.01) (see Tables 6
and 7).
Applicability
The applicability of the scale was determined by calcu-
lating the proportion of participants who did not provide
answers to all questions of the scale. As this did not hap-
pen, applicability of the SEPS was 100 %.
The participants took an average of 30–45 min to
complete the scale. While using a five-point Likert Scale,
22 participants (73.3 %) reported that they experienced no
distress when completing the scale, 5 (16.7 %) reported
feeling “a little” distress and only 3 (10 %) reported experi-
encing “moderate” distress.
Discussion
The aim of this work was to validate the SEPS for the Por-
tuguese population and provide to Portuguese mental
health professionals an instrument to assess and monitor
the dimensions of psychotic symptoms and actual effects of
treatment in individuals. Like the original questionnaire,
the validation of the European Portuguese version of SEPS
started with the formulation of detailed definitions of the
construct, derived from medical and psychological heuris-
tics and supported by previous research regarding system-
atic observation and analysis of the relevant domains of
behavior. Subsequently the Portuguese version of SEPS
underwent a psychometric analysis to determine its validity,
reliability and applicability.
Validity assessment
To examine validity, we used the Trinitarian model adopted
by the American Psychological Association, which divides
the validity of a psychometric instrument into content val-
idity, criterion validity and construct validity.
Table 6 Correlations between the subscales of the SEPS and







Positive impact 0.17 0.40* −0.10 0.13 0.37
Negative impact 0.74** −0.43* 0.53** 0.75** 0.55**
Positive support 0.04 0.39* −0.01 0.14 0.06
Negative support 0.52** −0.12 0.13 0.45* 0.55**
Positive dimensions −0.20 0.40* −0.12 −0.21 0.07
Negative dimensions 0.41* −0.20 0.35 0.41* 0.39*
*p <.05; **p <.01
Table 7 Correlations between the subscales of the SEPS and







Positive impact 0.21 −0.29 −0.20 0.18
Negative impact 0.24 0.44* 0.47** 0.41*
Positive support 0.13 −0.13 0.20 0.28
Negative support 0.16 0.22 0.18 0.10
Positive dimensions 0.20 −0.23 −0.16 0.17
Negative dimensions 0.51** 0.14 0.45* 0.50**
*p <.05; **p <.01
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Content validity
Regarding content validity, procedures such as spoken
reflection and independent back-translation required in
psychometric practice were followed. These processes
ensured that the test items do not undergo semantic and
conceptual deviations from the original scale and are
prepared to fit to the definitions of the construct. The
Portuguese version of SEPS also provides a representa-
tive sample of a finite universe of behaviors (Subjective
Experiences of Psychosis).
Criterion validity
After ensuring the content validity of the Portuguese
version of SEPS, we looked at whether the assessed con-
struct is subject to appropriate behavioral representation,
checking if the two factors that are defined theoretically
can be replicated with the empirical data from our sam-
ple. For this we carried out a factor analysis using the
principal components method, and adopting the eigen-
values and minimum correlation coefficients used by the
authors in the original scale [1]. As expected, there was
a clear division between positive and negative dimen-
sions (two factors). This also happened in the validation
study of the original version of SEPS [1]. This result
ensured that the Portuguese version of SEPS is a legitim-
ate and appropriate representation of the measured the-
oretical construct, i.e., it has construct validity.
Concurrent validity
We also intended to determine whether the Portuguese
version of SEPS is effective to predict the specific perform-
ance of a subject. The subject’s performance was assessed
concurrently (concurrent validity) through independent
scales already validated for the Portuguese population that
assess constructs or concepts present in SEPS. In general,
the negative dimensions of SEPS were positively correlated
with general measures of symptoms (BPRS, BSI), func-
tionality (FAST), depression (BPRS, BDI-II), anxiety
(BPRS, BSI) and psychoticism (BSI), and negatively corre-
lated with the measure of recovery (RAS).
The positive dimensions of SEPS, despite positive corre-
lations with the measure of recovery, were not always
negatively correlated with measures of symptoms. That is
in line with previous findings describing no direct correl-
ation between observer ratings of symptoms and subject-
ive self-report of being in recovery [17]. Such occurrence
is also not surprising when considering that some positive
symptoms are hypothesised to shield people from low
self-esteem, in line with the so called ‘protective’ function
of a lack of insight in psychosis [8, 36]. In fact, it has been
identified that, in schizophrenia patients, increase in self-
awareness and insight is a risk factor for depression and
suicide [16, 37]. Additionally, the awareness of symptoms
has been found to be influenced by an individual’s coping
style, with patients unaware of their symptoms having a
greater preference for positive reappraisal [38].
All instruments used in the criterion validity of SEPS
had, in our sample, internal consistency values consid-
ered appropriate. Thus, we can say that the Portuguese
version of SEPS shows criterion-related validity.
Reliability
To assess the reliability of the Portuguese version of SEPS
we verified its temporal constancy measured by test-retest
and internal consistency using Chronbach’s alpha. Using
DeVellis parameters [39] internal consistency values consid-
ered appropriate for the positive and negative components
of subscales of “Impact of Experiences” and “Dimensions of
Experiences” (α >0.80), and acceptable values (α >0.6) for
the positive and negative components of the subscale
“Impact of Support in Experiences” were obtained.
The lowest values of Cronbach’s alpha obtained for the
subscale “Impact of Support in Experiences” can be
explained by the different dimensions assessed by this
subscale. In the remaining subscales, negative parameters
were usually associated with the presence of symptoms
and positive at higher levels of recovery, thereby obtaining
good correlations between the positive and the negative
items from these subscales. This lends support to the good
levels of internal consistency found. However, in the Sub-
scale “Impact of Support in Experiences” the positive and
negative items are not necessarily interrelated because
they refer to aspects (medication, social support, use of al-
cohol or drugs and religious beliefs) that are not directly
associated with the symptoms. This may explain the oppos-
ite responses from a participant. The test-retest reliability
proved to be very good for all components of the subscales
of SEPS. Thus, with regard to reliability, the Portuguese
version of SEPS has good internal consistency and very
good temporal constancy.
Applicability
All participants responded to all the questions of scale,
i.e., the Portuguese version of SEPS has 100 % of
applicability.
Limitations and strengths
The major limitations of this study are the small sample
size given the scarcity of subjects that accepted inclusion
in the study, the deteriorated clinical condition of some
patients compromising the collection of data and the
drop-outs.
The inclusion of patients presenting different diagnosis
along the psychotic spectrum (schizophrenia, schizoaffec-
tive, brief psychotic disorder and bipolar disorder with
psychotic features), represent a major strength of the
Portuguese version of SEPS, expanding the applicability of
its original version.
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Conclusions
From the analyses described above, despite a small sam-
ple size, we can assume that the European Portuguese
version of SEPS has good psychometric properties and
can be a useful scale for assessing and monitoring
dimensions of psychotic symptoms. The Portuguese
version of the SEPS may be useful to measure the recov-
ery status of individuals during treatment, allowing the
assessment of the negative impact of psychotic experi-
ences, according to the patient’s own perspective. It also
enables to tailor treatment to each particular individual
(treatment, family, friends, etc.), allowing long-term and
sustained improvement in the prognosis of patients with
psychotic symptoms.
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